Botulinum toxin intravesicular - UroGen

Drug Profile

Botulinum toxin intravesicular - UroGen

Alternative Names: BotuGel™; TCgel+botulinium toxin

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraCoat
  • Developer UroGen Pharma
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Interstitial cystitis; Overactive bladder

Most Recent Events

  • 19 Oct 2016 UroGen Pharma withdraws prior to enrolment a phase I/II trial in Overactive bladder in Israel (NCT02674269)
  • 15 Mar 2016 Biomarkers information updated
  • 28 Feb 2016 UroGen Pharma terminates a phase I/II trial for Overactive bladder in Israel (NCT02179099)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top